Featured Research

from universities, journals, and other organizations

A new form of aspirin to overcome 'aspirin resistance'

Date:
September 4, 2013
Source:
American Chemical Society
Summary:
Scientists are reporting development of a new form of aspirin -- taken daily by about 60 million people in the United States alone to reduce the risk of heart attack and stroke -- that could extend aspirin's benefits to people who may not respond to the drug.

Scientists are reporting development of a new form of aspirin -- taken daily by about 60 million people in the United States alone to reduce the risk of heart attack and stroke -- that could extend aspirin's benefits to people who may not respond to the drug. Their advance toward coping with "aspirin resistance" appears in the journal ACS Nano.

Related Articles


Shiqi Peng, Ming Zhao and colleagues note that aspirin lowers cardiovascular disease risk by keeping blood cells called platelets from clumping and forming clots. But some experts believe that aspirin doesn't work for millions of people, who may switch to more costly, potent prescription drugs with more serious side effects. Scientists have tried to address aspirin resistance by combining it with other drugs. But Peng and Zhao say that the problem remains. Their research group decided to modify aspirin in an effort to make it work for more people.

They linked aspirin to a carrier consisting of a fragment of protein that can transport aspirin directly to damaged parts of blood vessels where clots form. Experiments with laboratory rats, stand-ins for humans in such early tests, showed that the carrier delivered aspirin to areas of blood vessels where clots were forming. It released aspirin inside the developing clot and stopped the clot-formation process.

The authors acknowledge funding from the Engineering Research Center of Endogenous Prophylactic of the Ministry of Education of the People's Republic of China, PHR (IHLB), the National Natural Science Foundation and the Beijing Natural Science Foundation and Special Project of China.


Story Source:

The above story is based on materials provided by American Chemical Society. Note: Materials may be edited for content and length.


Journal Reference:

  1. Shaoming Jin, Yaonan Wang, Haimei Zhu, Yuji Wang, Shurui Zhao, Ming Zhao, Jiawang Liu, Jianhui Wu, Wen Gao, Shiqi Peng. Nanosized Aspirin-Arg-Gly-Asp-Val: Delivery of Aspirin to Thrombus by the Target Carrier Arg-Gly-Asp-Val Tetrapeptide. ACS Nano, 2013; 130829111502006 DOI: 10.1021/nn402171v

Cite This Page:

American Chemical Society. "A new form of aspirin to overcome 'aspirin resistance'." ScienceDaily. ScienceDaily, 4 September 2013. <www.sciencedaily.com/releases/2013/09/130904130335.htm>.
American Chemical Society. (2013, September 4). A new form of aspirin to overcome 'aspirin resistance'. ScienceDaily. Retrieved March 5, 2015 from www.sciencedaily.com/releases/2013/09/130904130335.htm
American Chemical Society. "A new form of aspirin to overcome 'aspirin resistance'." ScienceDaily. www.sciencedaily.com/releases/2013/09/130904130335.htm (accessed March 5, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, March 5, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Newsy (Mar. 5, 2015) A survey of Boston mothers and toddlers found that 15 percent of two-year-olds drink coffee and 2.5 percent of 1-year-olds. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins